Janus Kinase Inhibitor [EPC] — Patent Landscape

Aggregated US Orange Book patent estate across every drug in the janus kinase inhibitor [epc] class. 27 active patents protecting 3 drugs. First major cliff: 2031. Daily refresh.

3
Drugs in class
27
Active US patents
58/100
Avg vulnerability
$1.2B
Annual revenue covered

Originators

Eli Lilly 17 patents Japan Tobacco 1 patents

Cliff calendar — next 15 years

2
29
7
31
9
32
6
34
3
36

Drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Olumiant
baricitinib
 Eli Lilly 17 62 $1.2B 2029-03-10
ABROCITINIB — 9 31 — 2034-02-19
Corectim
DELGOCITINIB
 Japan Tobacco 1 81 — 2031-09-19

Most attackable patents

Patent Drug Type Vuln Expiry
8609647 Corectim method of use 81 2031-09-19
9737469 Olumiant method of use 76 2031-11-02
11806555 Olumiant method of use 76 2031-11-02
11806555 Olumiant method of use 76 2031-11-02
9737469 Olumiant method of use 76 2031-11-02
9737469 Olumiant method of use 76 2031-11-02
11806555 Olumiant method of use 76 2031-11-02
8420629 Olumiant method of use 75 2029-03-10
8420629 Olumiant method of use 75 2029-03-10
9089574 Olumiant method of use 70 2032-11-30

Strongest defences

Patent Drug Type Vuln Expiry
8158616 Olumiant composition of matter 4 2032-05-31
8158616 Olumiant composition of matter 4 2032-05-31
9035074 ABROCITINIB composition of matter 12 2036-01-14
9035074 ABROCITINIB composition of matter 12 2036-01-14
9035074 ABROCITINIB composition of matter 12 2036-01-14
9545405 ABROCITINIB composition of matter 12 2034-02-19
9545405 ABROCITINIB composition of matter 12 2034-02-19
9545405 ABROCITINIB composition of matter 12 2034-02-19
8158616 Olumiant composition of matter 12 2032-05-31
9549929 ABROCITINIB method of use 70 2034-02-19

Related